The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome
Open accessAbstract
Antisense oligonucleotide administration reduces seizures and SUDEP incidence in a mouse model of Dravet syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The use of antisense oligonucleotides to increase the production of translated mRNA, termed Targeted Augmentation of Nuclear Gene Output (TANGO), has been used successfully in an animal model of Dravet syndrome to increase the production of sodium channels 239”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [239]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse modelPreprint
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 680
The core Dravet syndrome phenotype
Dravet, C. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.02994.x · Cited by 630
Cooper, M. S., McIntosh, A. M., Crompton, D. E., McMahon, J. M., Schneider, A., Farrell, K., Ganesan, V., Gill, D. S., Kivity, S., Lerman‐Sagie, T., et al. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.10.006 · Cited by 323
Wirrell, E. C., Laux, L., Donner, E. J., Jetté, N., Knupp, K. G., Meskis, M. A., Miller, I., Sullivan, J. E., Welborn, M., & Berg, A. T. (2017) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2017.01.025 · Cited by 287
The genetics of Dravet syndrome
Marini, C., Scheffer, I. E., Nabbout, R., Suls, A., Jonghe, P. D., Zara, F., & Guerrini, R. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.02997.x · Cited by 276
Incidence of Dravet Syndrome in a US Population
Wu, Y. W., Sullivan, J., McDaniel, S. S., Meisler, M. H., Walsh, E. M., Li, S. X., & Kuzniewicz, M. W. (2015) · Pediatrics · doi:10.1542/peds.2015-1807 · Cited by 248
Colasante, G., Lignani, G., Brusco, S., Berardino, C. D., Carpenter, J. C., Giannelli, S. G., Valassina, N., Bido, S., Ricci, R., Castoldi, V., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.018 · Cited by 246
Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy
Corey, D. R. (2017) · Nature Neuroscience · doi:10.1038/nn.4508 · Cited by 242
Cannabinoids in treatment-resistant epilepsy: A review
O’Connell, B. K., Gloss, D. S., & Devinsky, O. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.11.012 · Cited by 228
Lim, K., Zhou, H., Jeon, H. Y., Kach, J., Jing, E., Weyn‐Vanhentenryck, S. M., Downs, M., Corrionero, A., Oh, R. S., Scharner, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17093-9 · Cited by 216
Self-citationMeng, H., Xu, H., Yu, L., Lin, G., He, N., Su, T., Shi, Y., Li, B., Wang, J., Liu, X., et al. (2015) · Human Mutation · doi:10.1002/humu.22782 · Cited by 207
From genotype to phenotype in Dravet disease
Gataullina, S., & Dulac, O. (2016) · Seizure · doi:10.1016/j.seizure.2016.10.014 · Cited by 179
Oligonucleotide therapies for disorders of the nervous system
Khorkova, O., & Wahlestedt, C. (2017) · Nature Biotechnology · doi:10.1038/nbt.3784 · Cited by 179
Mistry, A. M., Thompson, C. H., Miller, A. R., Vanoye, C. G., George, A. L., & Kearney, J. A. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.01.006 · Cited by 177
Skluzacek, J. V., Watts, K. P., Parsy, O., Wical, B., & Camfield, P. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03012.x · Cited by 170
Nonintegrating Gene Therapy Vectors
Athanasopoulos, T., Munye, M. M., & Yáñez‐Muñoz, R. J. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.007 · Cited by 134
Not all SCN1A epileptic encephalopathies are Dravet syndrome: Early profound Thr226Met phenotype
Sadleir, L. G., Mountier, E. I., Gill, D., Davis, S., Joshi, C., DeVile, C., Kurian, M. A., Study, F. T. D., Mandelstam, S., Wirrell, E., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004331 · Cited by 131
TheSCN1Avariant database: a novel research and diagnostic tool
Claes, G. R. F., Deprez, L., Suls, A., Baets, J., Smets, K., Dyck, T. V., Deconinck, T., Jordanova, A., & Jonghe, P. D. (2009) · Human Mutation · doi:10.1002/humu.21083 · Cited by 128
Carvill, G. L., Engel, K. L., Ramamurthy, A., Cochran, J. N., Roovers, J., Stamberger, H., Lim, N. T. Y., Schneider, A., Hollingsworth, G., Holder, D. H., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.10.023 · Cited by 119
SCN1A gain of function in early infantile encephalopathy
Berecki, G., Bryson, A., Terhag, J., Maljevic, S., Gazina, E. V., Hill, S., & Petrou, S. (2019) · Annals of Neurology · doi:10.1002/ana.25438 · Cited by 94
Guerrini, R., & Aicardi, J. F. (2003) · Journal of Clinical Neurophysiology · doi:10.1097/00004691-200311000-00007 · Cited by 92
Nonsense-mediated mRNA decay at the crossroads of many cellular pathways
Lejeune, F. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.4.015 · Cited by 82
Severe myoclonic epilepsy in infancy (Dravet syndrome) 30 years later
Dravet, C., Bureau, M., Bernardina, B. D., & Guerrini, R. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.02993.x · Cited by 77
Hawkins, N. A., Zachwieja, N. J., Miller, A. R., Anderson, L. L., & Kearney, J. A. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006398 · Cited by 72
Cacna1g is a genetic modifier of epilepsy in a mouse model of Dravet syndrome
Calhoun, J. D., Hawkins, N. A., Zachwieja, N. J., & Kearney, J. A. (2017) · Epilepsia · doi:10.1111/epi.13811 · Cited by 58
Intravitreal Injection of Splice-switching Oligonucleotides to Manipulate Splicing in Retinal Cells
Gérard, X., Perrault, I., Münnich, A., Kaplan, J., & Rozet, J. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.24 · Cited by 34
Stiripentol: A Novel Antiseizure Medication for the Management of Dravet Syndrome
Buck, M. L., & Goodkin, H. P. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019856008 · Cited by 30
Emerging drugs for the treatment of Dravet syndrome
Brigo, F., Striano, P., Balagura, G., & Belcastro, V. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1552937 · Cited by 28
Chronic Toxicity Assessment of 2′- O -Methoxyethyl Antisense Oligonucleotides in Mice
Zanardi, T. A., Kim, T., Shen, L., Serota, D. G., Papagiannis, C. N., Park, S., Kim, Y., & Henry, S. P. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0706 · Cited by 22
Flagged first, then by citations
1 of the 30 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- C. Dravet, M. Bureau, H. Oguni, Y. Fukuyama, O. Cokar, Severe myoclonic epilepsy in infancy: Dravet syndrome. Adv. Neurol. 95, 71–102 (2005).
Cited by
Sorted by citations
Lauffer, M. C., van Roon‐Mom, W., Aartsma-Rus, A. M., & Collaborative, N. =. 1. (2024) · Communications Medicine · doi:10.1038/s43856-023-00419-1 · Cited by 295
International consensus on diagnosis and management of Dravet syndrome
Wirrell, E. C., Hood, V., Knupp, K. G., Meskis, M. A., Nabbout, R., Scheffer, I. E., Wilmshurst, J., & Sullivan, J. (2022) · Epilepsia · doi:10.1111/epi.17274 · Cited by 249
Sodium channelopathies in neurodevelopmental disorders
Meisler, M. H., Hill, S. F., & Yu, W. (2021) · Nature reviews. Neuroscience · doi:10.1038/s41583-020-00418-4 · Cited by 210
Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum
Guerrini, R., Conti, V., Mantegazza, M., Balestrini, S., Galanopoulou, A. S., & Benfenati, F. (2023) · Physiological Reviews · doi:10.1152/physrev.00063.2021 · Cited by 196
The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications
Brunklaus, A., Brünger, T., Feng, T., Fons, C., Lehikoinen, A., Panagiotakaki, E., Vintan, M.-A., Symonds, J., Andrew, J., Arzimanoglou, A., et al. (2022) · Brain · doi:10.1093/brain/awac210 · Cited by 167
Metadata
- Authors
- Han, Z., Chen, C., Christiansen, A., Ji, S., Lin, Q., Anumonwo, C., Liu, C., Leiser, S. C., Meena, Aznarez, I., Liau, G., & Isom, L. L.
- Affiliations
- Stoke Therapeutics Inc., Bedford, MA 01730, USA.
- University of Michigan (US)
- Stoke Therapeutics, Inc. (United States) (US)
- Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109, USA.
- PsychoGenics Inc., Paramus, NJ 07652, USA.
- Corresponding author
- Isom, Lori L.
- Venue
- Science Translational Medicine
- Published
- 2020-08-26
- Volume
- 12
- Issue
- 558
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3081439212
- Cited by
- 341
- References
- 30
- Citations by year
- 2026: 47 · 2025: 59 · 2024: 52 · 2023: 57 · 2022: 66 · 2021: 52 · 2020: 8
- FWCI
- 33.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Funders
- Stoke Therapeutics (N/A)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- antisense oligonucleotides, Dravet syndrome, SCN1A, sodium channel alpha subunit, seizures, sudden unexpected death in epilepsy, tango, gene-specific therapy, mouse model
- MeSH terms
- Sudden Unexpected Death in Epilepsy, Animals, Epilepsies, Myoclonic, Mice, Inbred C57BL, Seizures, Incidence, Oligonucleotides, Antisense, Mice, NAV1.1 Voltage-Gated Sodium Channel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
